INAMED CORP
8-K, 2000-02-14
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Previous: CERIDIAN CORP, SC 13G/A, 2000-02-14
Next: INAMED CORP, S-3, 2000-02-14



<PAGE>   1

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported): February 14, 2000

                               INAMED CORPORATION
- ------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

              Delaware                               59-0929629
- ------------------------------------------------------------------------------
(State of Incorporation or Organization)     (IRS Employer Identification No.)

                                   001-09741
- ------------------------------------------------------------------------------
                            (Commission File Number)

5540 Ekwill Street - Suite D, Santa Barbara, California               93111-2919
- -------------------------------------------------------------------------------
   (Address of principal executive offices)                           (Zip Code)

                                 Not Applicable
- -------------------------------------------------------------------------------
         (Former Name or Former Address, if Changed Since Last Report)
<PAGE>   2
Item 5.  Other Events.

     The Registrant entered into a Letter Agreement, dated February 14, 2000,
with several affiliates of Appaloosa Management L.P. (the "Appaloosa
Affiliates"), with respect to the shares of common stock, par value $0.01,
beneficially owned by the Appaloosa Affiliates pursuant to which the Registrant
has agreed to register those shares. The Letter Agreement is attached hereto as
Exhibit 99.1.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.
    (a)  Not applicable
    (b)  Not applicable
    (c)  Exhibits:

         The following exhibits are filed herewith:

Exhibit       Description

99.1          Letter Agreement, dated February 14, 2000, by and among Inamed
              Corporation, Appaloosa Investment Limited Partnership I, Palomino
              Fund Ltd., Palomino Investment Holdings Ltd. and Tersk LLC.
<PAGE>   3
                                   SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                         INAMED CORPORATION


                                        BY: /s/ David E. Bamberger
                                            ----------------------

                                            Name: David E. Bamberger
                                            Title: Senior Vice President,
                                                   Secretary and General Cousel

Date: February 14, 2000
<PAGE>   4
                                 EXHIBIT INDEX


     99.1      Letter Agreement, dated February 14, 2000, by and among Inamed
               Corporation, Appaloosa Investment Limited Partnership I, Palomino
               Fund Ltd., Palomino Investment Holdings Ltd. and Tersk LLC.



<PAGE>   1
                               INAMED CORPORATION
                            11 Penn Plaza, Suite 946
                            New York, New York 10001


                                February 14, 2000



Appaloosa Investment Limited Partnership I
Palomino Fund Ltd.
Palomino Investment Holdings Ltd.
Tersk LLC
26 Main Street
Chatham, New Jersey 07928


                             Re: Inamed Corporation
                                 ------------------

Dear Mr. Bolin:

     Reference is hereby made to the registration rights obligations of Inamed
Corporation, a Delaware corporation (the "Company"), under, without limitation,
(i) the several warrant agreements between you and the Company (the "Warrants")
providing for the purchase of shares of common stock, par value $.01 per share,
of the Company (the "Common Stock"), (ii) the letter agreement between the
Company and Appaloosa Management L.P., dated July 2, 1997 (the "July 2, 1997
Letter Agreement"), and (iii) the several waiver letters dated October 25, 1999
between you and the Company (the "Waiver Letters"). Each of you and the Company
hereby agree to amend such obligations as follows:

     (1)  The Company will file a registration statement (the "Registration
          Statement") on Form S-3, or Form S-1 if necessary, under the
          Securities Act of 1933, as amended (the "Securities Act"), on or about
          February 14, 2000 with respect to 2,000,000 shares of Common Stock
          held in the aggregate by you, which shares are to be offered on a
          delayed or continuous basis pursuant to Rule 415 of the Securities
          Act, and the Company will use its best efforts to cause such
          registration statement to be declared effective under the Securities
          Act as promptly as practicable after the filing thereof and will keep
          such Registration Statement continuously effective under the
          Securities Act, subject to customary limitations, for such period of
          time as you hold the Warrants or the Common Stock previously issued or
          issuable thereunder.

     (2)  Within 45 days following the effective date of the Registration
          Statement (the "First Registration Period"), the Company will file a
          registration statement for such number of additional shares of Common
          Stock as requested by you reasonably prior to the
          end of the First Registration Period; provided that if in the good
<PAGE>   2
          faith determination of Chase H&Q, or such other financial advisor/
          investment banking firm of national standing mutually agreed to by
          the Company and you (the "Investment Bank"), there has been a
          material decline in the market value of the Common Stock of the
          Company or a material disruption in the trading activity of such
          stock, or any event or development which could reasonably be expected
          to result in any such decline or disruption, or in the view of the
          Investment Bank the registration of such shares of Common Stock could
          reasonably be expected to have a material adverse effect on the
          market value or trading activity of the Common Stock (each, an
          "Adverse Market Effect"), the Company will not be required to register
          your shares of Common Stock pursuant to your request. In such event,
          the Company and you agree to reduce the number of shares of Common
          Stock to be registered thereunder as required in the view of the
          Investment Bank in order to eliminate the Adverse Market Effect, which
          reduction could result in none of the requested shares of Common Stock
          becoming registered at that time.

          Within 45 days following the later of the end of the First
          Registration Period and the effective date of any registration
          statement filed pursuant to the preceding paragraph (the "Second
          Registration Period"), the Company will file a registration statement
          for such number of additional shares of Common Stock as requested by
          you reasonably prior to the end of the Second Registration Period;
          provided that if such request for registration is for more than
          2,000,000 shares and the Investment Bank determines that such
          registration would have an Adverse Market Effect, the Company and you
          agree to reduce the number of shares of Common Stock to be registered
          as required in the view of the Investment Bank in order to eliminate
          the Adverse Market Effect, which reduction shall not reduce the number
          of shares to be registered below 2,000,000 shares.

          Within 45 days following the later of the end of the Second
          Registration Period and the effective date of any registration
          statement filed pursuant to the preceding paragraph (the "Third
          Registration Period"), the Company will file a registration statement
          for such number of additional shares of Common Stock as requested by
          you reasonably prior to the end of the Third Registration Period;
          provided that if such request for registration is for more than
          2,000,000 shares and the Investment Bank determines that such
          registration would have an Adverse Market Effect, the Company and you
          agree to reduce the number of shares of Common Stock to be registered
          as required in the view of the Investment Bank in order to eliminate
          the Adverse Market Effect, which reduction shall not reduce the number
          of shares to be registered below 2,000,000 shares.
<PAGE>   3
          Within 45 days following the later of the end of the Third
          Registration Period and the effective date of any registration
          statement filed pursuant to the preceding paragraph (the "Fourth
          Registration Period"), the Company will file a registration statement
          for such number of additional shares of Common Stock as requested by
          you reasonably prior to the end of the Fourth Registration Period;
          provided that if such request for registration is for more than
          2,000,000 shares and the Investment Bank determines that such
          registration would have an Adverse Market Effect, the Company and you
          agree to reduce the number of shares of Common Stock to be registered
          as required in the view of the Investment Bank in order to eliminate
          the Adverse Market Effect, which reduction shall not reduce the number
          of shares to be registered below 2,000,000 shares.

          Notwithstanding the foregoing, the Company will be obligated to have
          one or more registration statements declared effective with respect to
          all of your shares of Common Stock not later than December 31, 2000.
          Any shares of Common Stock registered pursuant to this paragraph (2)
          will be made in accordance with the terms and conditions contained in
          paragraph (1) above, including the Company's obligations to keep such
          registration statements continuously effective under the Securities
          Act, as provided therein.

     (3)  Subject to items (1) and (2) above and notwithstanding anything to the
          contrary contained in the Warrants, the July 2, 1997 Letter Agreement
          or the Waiver Letters, you are entitled to an unlimited number of
          demand registrations with respect to your shares of Common Stock
          previously issued or issuable under the Warrants. The Company will
          bear all costs and expenses of such registrations.
<PAGE>   4
     Please indicate your acknowledgement and agreement to the foregoing by
signing this letter agreement in the space provided below and returning a copy
to the Company.

                                        Sincerely yours,

                                        INAMED CORPORATION

                                        By: /s/ David E. Bamberger
                                            ----------------------
                                            David E. Bamberger
                                            Senior Vice President
                                            Secretary and General Counsel

APPALOOSA INVESTMENT LIMITED PARTNERSHIP I
PALOMINO FUND LTD.
PALOMINO INVESTMENT HOLDINGS LTD.
TERSK LLC

By: Appaloosa Management L.P.

By: Appaloosa Partners Inc.
    Its General Partner

By: /s/ James E. Bolin
    --------------------
    James E. Bolin
    Vice President


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission